Trials / Completed
CompletedNCT02238366
Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer
A Non-interventional, Multi-centric, Observational, Prospective Study to Collect the Criteria on Which Renewal of GnRH Analogue Treatment With Triptorelin (Diphereline 3.75mg or Diphereline pr 11.25mg) is Made in Patients Recently Diagnosed With Prostate Cancer Requiring Androgen Deprivation Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 368 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect some parameters which may help to provide guidance on how Androgen Deprivation Therapy (ADT) drugs are renewed and physician satisfaction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | triptorelin | This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency. |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2019-06-06
- Completion
- 2019-06-06
- First posted
- 2014-09-12
- Last updated
- 2019-07-25
Locations
7 sites across 1 country: Romania
Source: ClinicalTrials.gov record NCT02238366. Inclusion in this directory is not an endorsement.